当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Nadiyeh Rouhi
The use of biomarkers in basic and clinical analysis further as in clinical observe has become thus commonplace that their presence as primary endpoints in clinical trials is currently accepted nearly while not question. Within the case of specific biomarkers that are well characterized and repeatedly shown to properly predict relevant clinical outcomes across a range of treatments and populations, this use is entirely even and applicable. In several cases, however, the “validity” of biomarkers is assumed wherever, in fact, it ought to still be evaluated and reevaluated. This text can take into account the present abstract standing of biomarkers as clinical and diagnostic tools and as surrogate endpoints in clinical analysis with the goal of providing context for decoding studies that trust heavily on such biological measures.